Actinium Pharmaceuticals Presents New Preclinical Data for ATNM-400, Demonstrating Potent Anti-Tumor Activity and Favorable Tolerability Profile in Breast Cancer Models.

Actinium Pharmaceuticals presented new preclinical data for ATNM-400, an Actinium-225 based antibody radioconjugate, at the San Antonio Breast Cancer Symposium. The data showed potent anti-tumor activity and a favorable tolerability profile across various breast cancer models, including hormone receptor-positive and triple-negative breast cancer. The company plans to accelerate development of ATNM-400 and is also developing Actimab-A in combination with other therapies for the treatment of various cancers.